Novelion Therapeutics Inc. announced Chief Executive Officer Mary Szela has resigned for personal reasons, effective immediately. To lead the company until a permanent CEO is appointed, the Board announced the creation of an interim Office of the Chief Executive Officer, comprised of Jeffrey Hackman, Novelion's Chief Operating Officer, Jason Aryeh, Chairman of the Board of Directors and Mark Corrigan, Director. The Board has also formed a search committee, which has commenced efforts to identify candidates who will bring strong strategic and operational direction to the enterprise.

Novelion appointed Murray Stewart, M.D. as Executive Vice President, Head of R&D, effective November 27, 2017. Dr. Stewart will lead the company's clinical development activities, provide strategic regulatory guidance for the pipeline and commercial product initiatives, and maintain oversight of global medical affairs, publications and registry activities. Dr. Stewart will join Novelion from GlaxoSmithKline (GSK) where he is currently chief medical officer with global responsibility for patient well-being across the vaccines, pharmaceutical and consumer business units.

Novelion appointed Suzanne Bruhn, PH.D. to its board of directors, effective October 1, 2017. Dr. Bruhn is president and chief executive officer of proclara biosciences, inc. prior to joining Proclara, dr. bruhn served as president and chief executive officer of Promedior, inc.